Lunai Bioworks is a biotechnology business committed to developing enhanced allogenic cell and gene therapies.
Lunai Bioworks has raised $20.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Lunai Bioworks's investors include Clemann Group.
Lunai Bioworks is headquartered in New York, United States.
Lunai Bioworks is a biotechnology business committed to developing enhanced allogenic cell and gene therapies.
Lunai Bioworks is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lunai Bioworks — Funding & Investors." VCBacked, April 15, 2026, https://www.vcbacked.co/company/lunai-bioworks. Accessed August 14, 2026.
VCBacked. (2026). Lunai Bioworks — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lunai-bioworks
{{cite web |title=Lunai Bioworks — Funding & Investors |url=https://www.vcbacked.co/company/lunai-bioworks |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated